FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 4 filers reported holding FATE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64 | -55.2% | 30 | 0.0% | 0.00% | – |
| Q2 2023 | $143 | -99.9% | 30 | -99.9% | 0.00% | -100.0% |
| Q1 2023 | $140,266 | +10673.1% | 24,608 | +18976.0% | 0.11% | +10500.0% |
| Q4 2022 | $1,302 | +30.2% | 129 | +330.0% | 0.00% | 0.0% |
| Q3 2022 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,000 | – | 30 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |